Health Care·Biotechnology·$3.7B
ACADIA Pharmaceuticals (ACAD) is a biotechnology company focused on developing innovative therapies for central nervous system disorders. With a market cap of $4 billion, ACAD plays a significant role in the healthcare sector, particularly in addressing unmet medical needs in mental health.
Earnings Per Share (EPS)
EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.
Revenue Growth
While specific revenue figures are not available, growth in revenue is crucial for assessing the company's market performance and product acceptance.
1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
8Q
EPS Beat Rate
100%
Avg EPS Surprise
+253.03%
Avg Stock Reaction
+1.65%
In the last quarter (Q4-2025), ACADIA reported an impressive EPS of $1.60, significantly beating estimates. The stock reacted positively, gaining 1.55% the following day.
Management Promises & Guidance
Overall, there is a strong expectation for ACAD to continue its trend of beating EPS estimates, given its recent performance. Investors are keenly watching for any updates on product pipeline and revenue growth.
Bull Case
If ACAD can deliver another strong EPS and positive updates on its pipeline, it could see a significant stock price increase, reflecting investor confidence.
Bear Case
Conversely, if the company fails to meet expectations or provides disappointing updates on its pipeline, it could lead to a decline in stock price, especially given the recent high EPS surprises.
Earnings Per Share (EPS)
N/AEPS is a key indicator of the company's profitability and financial health, which investors closely monitor.
Revenue Growth
N/AWhile specific revenue figures are not available, growth in revenue is crucial for assessing the company's market performance and product acceptance.
Pipeline Progress
N/AUpdates on clinical trials and product pipeline can significantly impact investor sentiment and stock performance.
The print will turn on these two things.
Q1
What will be the EPS for Q1-2026?
Given the company's history of beating EPS estimates, this figure will be critical in determining market sentiment and stock movement.
Q2
What updates will be provided on the product pipeline?
Investors are eager to hear about advancements in clinical trials, which can significantly impact future revenue and growth potential.
Why consensus could be wrong
The Street may be underestimating the potential for ACAD to deliver strong EPS due to its recent performance and pipeline advancements.
Supporting Evidence
ACAD has consistently surprised on EPS, with a 100% beat rate over the last four quarters.
The company's focus on innovative therapies positions it well for future growth, which may not be fully reflected in current estimates.
Key Risk
If the EPS exceeds $1.80, it could challenge the current consensus and lead to a reevaluation of the company's growth potential.
Pre-commit to what would confirm each case.
The upcoming earnings report is pivotal as it will either reinforce the company's growth story or raise doubts about its future prospects.
Bull Confirmed If
An EPS of $1.80 or higher would confirm the bull case, indicating strong operational performance.
Bear Confirmed If
An EPS below $1.20 would raise concerns about the company's growth trajectory and could confirm the bear case.
Implied Move
±N/A
There is currently no options market data available to gauge investor sentiment ahead of the earnings report.
Likely market behavior by outcome — not investment advice.
Beat & Raise
If ACAD beats expectations, history suggests a potential stock increase of around 1.65%, reinforcing investor confidence in the company's growth.
In-Line / Cautious
If results are in line with expectations, the market may react cautiously, leading to a muted response as investors await further guidance.
Miss
Should ACAD miss expectations, history indicates a potential decline, with an average drop of around 1.84%, reflecting investor disappointment.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
PARAMOUNT SKYDANCE C Class B
May 4, 2026